Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Organic cation transporter 1 (OCT1) is involved in pentamidine transport at the human and mouse blood-brain barrier (BBB).

Sekhar GN, Georgian AR, Sanderson L, Vizcay-Barrena G, Brown RC, Muresan P, Fleck RA, Thomas SA.

PLoS One. 2017 Mar 31;12(3):e0173474. doi: 10.1371/journal.pone.0173474. eCollection 2017.

2.

Understanding diabetes in patients with HIV/AIDS.

Kalra S, Kalra B, Agrawal N, Unnikrishnan A.

Diabetol Metab Syndr. 2011 Jan 14;3(1):2. doi: 10.1186/1758-5996-3-2.

3.

The role of environmental factors in insulin-dependent diabetes mellitus: an unresolved issue.

Kraine MR, Tisch RM.

Environ Health Perspect. 1999 Oct;107 Suppl 5:777-81. Review.

4.

New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review.

Lee EC, Walmsley S, Fantus IG.

CMAJ. 1999 Jul 27;161(2):161-4. Review. No abstract available.

5.

Insulin resistance and development of diabetes mellitus associated with megestrol acetate therapy.

Jain P, Girardi LS, Sherman L, Berelowicz M, Smith LG.

Postgrad Med J. 1996 Jun;72(848):365-7.

6.

Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model.

Fishman JA, Queener SF, Roth RS, Bartlett MS.

Antimicrob Agents Chemother. 1993 Jul;37(7):1543-6.

7.

Diabetic ketoacidosis following pentamidine therapy in a patient with the acquired immunodeficiency syndrome.

Lambertus MW, Murthy AR, Nagami P, Goetz MB.

West J Med. 1988 Nov;149(5):602-4. No abstract available.

Supplemental Content

Support Center